Reporter brief
Targeting mTOR With Everolimus and/or Physical Training for Preventing Postmenopausal Bone Loss and Accelerated Skeletal Aging: The RapaLoad Study
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No results are reported, so the study cannot be evaluated for whether the interventions prevent bone loss or other skeletal outcomes in postmenopausal women.
- The abstract provides only the study protocol and design; actual efficacy or safety findings are not presented.
- The timing and completion status of this trial are unclear from the material provided, leaving uncertainty about whether results are pending or unavailable.
Study design and sample
Rct; Human.
Healthy postmenopausal women aged 45-60 years with T-score >-3 and no history of hip, Colles' or symptomatic vertebral fractures within the last 6 months
- Design
- Rct
- Sample
- 136
- Journal
- Odense University Hospital
- Published
- Apr 7, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.